Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments-Reference-Cited by-同舟云学术

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

Published:2018-11-02 Issue:11 Volume:13 Page:e0206223
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yu Jong W.^ORCID,Bhattacharya Sabyasachi,Yanamandra Niranjan,Kilian David,Shi Hong,Yadavilli Sapna,Katlinskaya Yuliya,Kaczynski Heather,Conner Michael,Benson William,Hahn Ashleigh,Seestaller-Wehr Laura,Bi Meixia,Vitali Nicholas J.,Tsvetkov Lyuben,Halsey Wendy,Hughes Ashley,Traini Christopher,Zhou Hui,Jing Junping,Lee Tae,Figueroa David J.,Brett Sara,Hopson Christopher B.,Smothers James F.,Hoos Axel,Srinivasan Roopa

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference69 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;SM Ansell;The New England journal of medicine,2015

2. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy;MK Callahan;Journal of leukocyte biology,2013

3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck;RL Ferris;The New England journal of medicine,2016

4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;RS Herbst;Nature,2014

5. Improved survival with ipilimumab in patients with metastatic melanoma;FS Hodi;The New England journal of medicine,2010

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects;Cancer Immunology, Immunotherapy;2024-08-06

2. OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC‐38 murine colon carcinoma model;Cytometry Part A;2024-08-06

3. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy;Pharmaceuticals;2024-08-05

4. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments;Biochemical Pharmacology;2024-08

5. Physical and Psychological Stressors Increase Breast Tumor Growth but Differentially Alter Tumor Immunity;2024-07-25